Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy

Targeting tumor-associated macrophages (TAMs) is a promising strategy to modify the immunosuppressive tumor microenvironment and improve cancer immunotherapy. Monoamine oxidase A (MAO-A) is an enzyme best known for its function in the brain; small molecule MAO inhibitors (MAOIs) are clinically used for treating neurological disorders. Here we observe MAO-A induction in mouse and human TAMs. MAO-A-deficient mice exhibit decreased TAM immunosuppressive functions corresponding with enhanced antitumor immunity. MAOI treatment induces TAM reprogramming and suppresses tumor growth in preclinical mouse syngeneic and human xenograft tumor models. Combining MAOI and anti-PD-1 treatments results in synergistic tumor suppression. Clinical data correlation studies associate high intratumoral MAOA expression with poor patient survival in a broad range of cancers. We further demonstrate that MAO-A promotes TAM immunosuppressive polarization via upregulating oxidative stress. Together, these data identify MAO-A as a critical regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunotherapy.


Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences
Behavioural & social sciences Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative. For all studies samples size were defined on the basis of previous studies in the laboratory. For in vivo studies, between 4 to 10 mice per group were used dependent on the experimental design and were able to reach a significant level of 0.05. For in vitro studies, at least 3 mice/ biological group were used as cell donors with technical replicates that encompassed at least 2 wells per mouse. For human studies, at least 4 donors or patient samples per group were used.
No data were excluded for analysis.
All experiments were performed independently. Replicates of each individual experiment was stated in its figure legends. The experimental findings were reproduced with similar results. For single cell RNA sequencing, a mixture of 10 mice TII suspensions were combined for each group.
All mice were randomized. Within one experiment, all mice were age-and sex-matched. For human studies, all donors or patients are randomized.
Experiments were not performed in a blinded fashion. For mice in vivo studies, the investigators were aware of genotyping results. All data were analyzed by software with objective standard. Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants Population characteristics
All cell lines were tested negative for mycoplasma contamination.
No misidentified lines were used.
Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.
For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
All animals were maintained at the UCLA animal facilities and all animal experiments were approved by the Institutional Animal Care and Use Committee of UCLA.
Detailed patients information is provided in Supplementary Table, including collection date, age, diagnosis and staging.
Primary human ovarian cancer tumour samples were obtained from the operating room at the UCLA Medical Center from consenting patients using IRB-approved protocols (IRB# 10-000727).
Human peripheral blood mononuclear cells (PBMCs) of healthy donors were obtained from the CFAR Gene and Cellular Therapy Core Laboratory at UCLA, without identification information under federal and state regulations.